VKTX
$35.53
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
Intraday
Recent News
Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics
Each of these companies could benefit from this high-growth market over time.
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider
Viking Therapeutics, Inc. (VKTX) reached $36.01 at the closing of the latest trading day, reflecting a +1.07% change compared to its last close.
What to Know About This Obesity Drug Developer That Just Drew a New $7 Million Investment
Viking Therapeutics develops clinical-stage therapies for metabolic and endocrine disorders, aiming to address unmet medical needs.
3 Companies at the Forefront of the GLP-1 Pill Wars
The GLP-1 industry is accelerating growth as adoption rates continue to rise, and these three pharmaceuticals companies could be positioned to capitalize.
Why Is Viking Therapeutics (VKTX) Up 16.3% Since Last Earnings Report?
Viking Therapeutics (VKTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.